BC Innovations | Oct 31, 2017
Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Mouse studies suggest BuChE could help treat obesity. In a mouse model of high-fat diet-induced obesity, a calorie-restricted diet plus an adeno-associated viral (AAV) vector encoding BuChE decreased body weight and fat mass...
BC Week In Review | Oct 6, 2014
Company News

PharmAthene, Nanotherapeutics, U.S. Department of Defense deal

PharmAthene partnered with Nanotherapeutics to advance undisclosed biodefense products from both companies' portfolios. The partners said PharmAthene's pipeline of products to prevent and treat emerging infectious diseases and biodefense threats fits well with Nanotherapeutics' manufacturing...
BC Week In Review | Oct 29, 2012
Company News

Chesapeake PERL, U.S. Department of Defense neurology, biomanufacturing news

DoD's Defense Threat Reduction Agency (DTRA) awarded Chesapeake a contract to develop a recombinant butyrylcholinesterase (BChE) as a nerve agent countermeasure. The contact will fund development and production of the recombinant BChE in Chesapeake's PERLXpress...
BC Week In Review | Aug 13, 2012
Company News

PharmAthene other news

PharmAthene said the U.S. Department of Defense exercised an option to provide up to $2.5 million in funding. The money will be used to develop a mammalian cell-based advanced expression manufacturing system for the biotech's...
BC Week In Review | Jul 30, 2012
Clinical News

Bisnorcymserine: Phase I started

QR Pharma began a double-blind Phase I trial to evaluate single ascending-doses of 20, 40, 80, 160, 380, 490 and 600 mg bisnorcymserine in up to 56 healthy elderly volunteers. The company has exclusive, worldwide...
BC Innovations | Feb 2, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Acetylcholinesterase (AChE); butyrylcholinesterase (BuChE) Studies in vitro and in mice suggest amidine-oxime-based compounds could help reverse organophosphate nerve agent poisoning. Organophosphates including sarin...
BC Innovations | Feb 2, 2012
Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In two sets of gene and protein expression data...
BC Week In Review | Aug 22, 2011
Company News

PharmAthene other news

PharmAthene received an 18-month, $5.7 million contract under a U.S. Department of Defense Board Agency announcement to develop a mammalian cell-based manufacturing system for the biotech's rBChE program. rBChE is a recombinant form of a...
BioCentury | May 30, 2011
Emerging Company Profile

QR: Power of positivity

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety. The more advanced of the two...
BC Innovations | Dec 9, 2010
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Plant-based platform to generate recombinant human butyrylcholinesterase (BChE) A plant-based platform could provide a sustainable source of recombinant human BChE, an enzyme that prevents poisoning...
Items per page:
1 - 10 of 315